Biochemical efficacy and tolerability of allopurinol, benzbromarone and probenecid in gout.
Completed
- Conditions
- gout, hyperuricemia
- Registration Number
- NL-OMON25101
- Lead Sponsor
- drs M.K. ReindersDepartment of Clinical Pharmacy and Pharmacology,Medical Centre LeeuwardenPostbox 8888901 BR LeeuwardenThe Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 96
Inclusion Criteria
1. Age >18 year;
2. Diagnosis gout based on crystal evidence or ARA criteria;
Exclusion Criteria
1. Contra-indication for allopurinol, benzbromaron or probenecid;
2. Prior treatment with allopurinol, benzbromaron or probenecid.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Success rate on study medication consisting of patient tolerability and attainment of target level serum urate <0.30 mmol/l after 8 weeks treatment.
- Secondary Outcome Measures
Name Time Method 1. Serum urate lowering effect (% decrease) of the antihyperuricemic agent;<br /><br>2. tolerability of the antihyperuricemic agent (adverse drug reactions).<br>